Patterns of care and survival outcomes in patients with astroblastoma: an individual patient data analysis of 152 cases

• Published in: Child's nervous system 2017-08, Vol.33 (8), p.1295-1302
• Main Authors: Mallick, Supriya, Benson, Rony, Venkatesulu, Bhanuprasad, Melgandi, Wineeta, Rath, Goura K
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms - mortality; Brain Neoplasms - therapy; Child; Child, Preschool; Databases, Bibliographic; Disease-Free Survival; Humans; Infant; Infant, Newborn; Male; Medicine; Medicine & Public Health; Middle Aged; Neoplasms, Neuroepithelial - mortality; Neoplasms, Neuroepithelial - therapy; Neurosciences; Neurosurgery; Original Paper; Radiotherapy; Retrospective Studies; Sex Factors; Young Adult
• ISSN: 0256-7040; 1433-0350
• DOI: 10.1007/s00381-017-3410-5

Background Astroblastoma (AB) is a rare tumor with significant dilemma regarding diagnostic criteria, behavior, and optimum treatment. Materials and methods We searched PubMed, Google Search, and Cochrane Library for eligible studies with the following search words: astroblastoma, high-grade astroblastoma, and anaplastic astroblastoma till July 1, 2016, published in English language and collected data regarding age, sex, site of disease, pathological grade, treatment received, and survival. Results Data of 152 patients were retrieved from 63 publications. Median age was 16 years (range 0–71). Females were affected twice more frequently than male (70.3 vs. 29.7%). Tumors were most commonly located in the frontal (39%) followed by parietal lobe (26.7%). Fifty-two and 25% of the patients had headache and seizure at presentation, 76.3% of the patients underwent a gross total resection, 41 out of 89 had a high-grade tumor, and 56 patients received adjuvant radiation with a median dose of 54 Gy (range 20–72). Adjuvant chemotherapy was used in 23 patients. Temozolomide was the most common drug used in 30% of the patients. A combination of cisplatin, etoposide with vincristine, or ifosfamide was used in 17%. Median follow-up duration was 37 months (range 1–238). Median progression-free survival and OS were 36 and 184 months, respectively. Patients with a higher-grade tumor had significantly worse OS with HR 5.260 and p  = 0.001. Forty patients experienced local progression. Sixty-five percent patients underwent surgery while 50% underwent radiation as salvage. Conclusion AB has two distinct grades with higher-grade tumors having significantly poor survival. Maximal safe surgery followed by adjuvant radiation and temozolomide should be advocated for these tumors.